Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B
Clinical Gastroenterology and Hepatology · 2026-03 · 24 (3) · 701-712.e8
DOI: 10.1016/j.cgh.2025.06.014 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-03. Verfasst von Maria Kalafateli und 46 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, United Ki…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Fatty Liver. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Imperial College Healthcare NHS Trust, Medical Research Council, NIHR Imperial Biomedical Research Centre.
Abstract (Originalsprache)
BACKGROUND & AIMS: Chronic hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) commonly co-exist, with conflicting data in prevalence and disease severity. We aimed to investigate these discrepancies. METHODS: This multicenter study included consecutive patients with CHB from 19 European centers. A survey on standard of care for MASLD screening in CHB was circulated. RESULTS: A total of 1709 patients with CHB were included; median age, 53 years (interquartile range [IQR], 42-64); males, 60.7%; body mass index (BMI), 25.6 kg/m2 (IQR, 14-63 kg/m2); and 57.3% White. MASLD prevalence (1510 consecutive patients) was 42.3%. BMI (odds ratio [OR], 1.27; 95% confidence interval [CI], 1.19-1.36), ferritin (OR, 1.00; 95% CI, 1.00-1.00) and type 2 diabetes (OR, 2.60; 95% CI, 1.12-6.02) were independently associated with MASLD. The prevalence of advanced fibrosis was 18% (255/1420) in the whole cohort, 25.4% (162/639) among patients with CHB with MASLD, and 13.7% in those without MASLD. Independent predictors of advanced fibrosis were MASLD (OR, 2.76; 95% CI, 1.50-5.05), BMI (OR, 1.08; 95% CI, 1.02-1.15), alanine transaminase (OR, 1.01; 95% CI, 1.00-1.03), lower platelets (OR, 0.99; 95% CI, 0.98-0.99), insulin treatment (OR, 13.88; 95% CI, 2.95-65.28), and long-term antivirals (OR, 4.86; 95% CI, 2.40-9.85). During follow-up (48 months), only patients without MASLD showed significant liver stiffness measurement improvement over time (P < .001). Among patients with MASLD, Fibrosis-4 and liver stiffness measurement performed moderately at predicting advanced fibrosis (area under the receiver operating characteristic curve = 0.71 vs 0.70; P = .38) against histology. As standard of care, 68.4% of centers screened all patients with CHB for MASLD; 52.6% followed the same treatment indication in those with CHB and MASLD vs CHB only. CONCLUSIONS: In this large European cohort, MASLD and fibrosis were highly prevalent among patients with CHB, whereas MASLD aggravated liver fibrosis. Though screening strategies remain inconsistent, ferritin levels, increased BMI, and type 2 diabetes may inform on the presence of MASLD. Biomarkers showed modest performance in predicting fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, United Kingdom; Department of Hepatology, St Mary's Hospital, Imperial College…
- Oxford University Hospital, Oxford, United Kingdom.
- Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, United Kingdom.
- Faculty of Medicine, Université Paris Cité, Cochin Site, Paris, France.
- Royal Liverpool Hospital Liverpool, Liverpool, United Kingdom.
- Liver Unit, University of Foggia, Foggia, Italy.
Förderung
- Imperial College Healthcare NHS Trust
- Medical Research Council
- NIHR Imperial Biomedical Research Centre
- Imperial College London
- National Institute for Health and Care Research
Zitieren
APA
Kalafateli, M., Forlano, R., Barnes, E., Martinez-Gili, L., Lacey, M., Sigon, G., Mullish, B. H., Mallet, V., Parlati, L., Richardson, P., Forde, N., Serviddio, G., Villani, R., Lens, S., Buti, M., Vargas, E., Viganò, M., Loglio, A., Lampertico, P., …, & Manousou, P. (2026). Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 24(3), 701-712.e8. https://doi.org/10.1016/j.cgh.2025.06.014
Vancouver
Kalafateli M, Forlano R, Barnes E, Martinez-Gili L, Lacey M, Sigon G, et al. Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology. 2026;24(3):701-712.e8. doi:10.1016/j.cgh.2025.06.014
BibTeX
@article{Kalafateli2026,
author = {Kalafateli, Maria and Forlano, Roberta and Barnes, Eleanor and Martinez-Gili, Laura and Lacey, Madeleine and Sigon, Giordano and Mullish, Benjamin H and Mallet, Vincent and Parlati, Lucia and Richardson, Paul and Forde, Niamh and Serviddio, Gaetano and Villani, Rosanna and Lens, Sabela and Buti, Maria and Vargas, Elena and Viganò, Mauro and Loglio, Alessandro and Lampertico, Pietro and D'ambrosio, Roberta and Monico, Sara and Maffi, Gabriele and Lombardi, Rosa and Fracanzani, Anna Ludovica and De Luca, Chiara and Ingiliz, Patrick and Mangia, Alessandra and Leserre, Federica and Napolitano, Antonio Manuel and Piazzolla, Valeria and Russo, Francesco Paolo and Raimondo, Giovanni and Cacciola, Irene and Saitta, Carlo and Lemoine, Maud and Papatheodoridis, George and Papatheodoridi, Margarita and Samonakis, Dimitrios N and O'Donnell, Denise and O'Donoghue, Jennifer and Abeles, Robin Daniel and Pugliese, Nicola and Aghemo, Alessio and Berenguer, Marina and Brown, Ashley and Thursz, Mark R and Manousou, Pinelopi},
title = {Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {3},
pages = {701--712.e8},
doi = {10.1016/j.cgh.2025.06.014}
}
EUVIMED